ILLUMINA, INC. (ILMN) Spending and interest coverage
- R&D / revenue · 12 months: Value 21.36%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-28..
- Stock-based compensation / revenue · 12 months: Value 5.92%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-28..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-28; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 21.36% | Research and development expense / revenue. Period ending 2026-06-28. $960.00M ÷ $4.49B × 100 ≈ 21.36% |
| Stock-based compensation / revenue · 12 months | 5.92% | Share-based compensation / revenue. Period ending 2026-06-28. $266.00M ÷ $4.49B × 100 ≈ 5.92% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 960.00M USD | Research and Development Expense |
| Revenue | 4.49B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 266.00M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 883.00M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-28 | $960.00M | $4.49B | $266.00M | $883.00M | (m) | 21.36% | 5.92% | (m) | (m) |
| 2026-03-29 | $955.00M | $4.39B | $262.00M | $852.00M | (m) | 21.74% | 5.96% | (m) | (m) |
| 2025-12-28 | $967.00M | $4.34B | $275.00M | $807.00M | (m) | 22.27% | 6.33% | (m) | (m) |
| 2025-09-28 | $984.00M | $4.29B | $291.00M | $781.00M | (m) | 22.95% | 6.79% | (m) | (m) |
| 2025-06-29 | $1.01B | $4.28B | $304.00M | $1.29B | (m) | 23.53% | 7.10% | (m) | (m) |
| 2025-03-30 | $1.08B | $4.34B | $347.00M | $-558.00M | (m) | 24.95% | 8.00% | (m) | (m) |
| 2024-12-29 | $1.17B | $4.37B | $370.00M | $-833.00M | (m) | 26.74% | 8.46% | (m) | (m) |
| 2024-09-29 | $1.25B | $4.39B | $385.00M | $-1.17B | (m) | 28.56% | 8.77% | (m) | (m) |
| 2024-06-30 | $1.31B | $4.43B | $389.00M | $-2.67B | (m) | 29.69% | 8.78% | (m) | (m) |
| 2024-03-31 | $1.35B | $4.49B | $383.00M | $-1.12B | $75.00M | 30.09% | 8.52% | -14.88× | Reported |
| 2023-12-31 | $1.35B | $4.50B | $380.00M | $-1.07B | $77.00M | 30.06% | 8.44% | -13.88× | Reported |
| 2023-10-01 | $1.36B | $4.46B | $386.00M | $-1.03B | $68.00M | 30.44% | 8.65% | -15.18× | Reported |
| 2023-07-02 | $1.37B | $4.46B | $382.00M | $-3.94B | $53.00M | 30.71% | 8.56% | -74.26× | Reported |
| 2023-04-02 | $1.34B | $4.45B | $367.00M | $-4.43B | $40.00M | 30.10% | 8.25% | -110.67× | Reported |
| 2023-01-01 | $1.32B | $4.58B | $366.00M | $-4.18B | $26.00M | 28.82% | 7.98% | -160.73× | Reported |
| 2022-10-02 | $1.32B | $4.70B | $364.00M | $-4.01B | $30.00M | 28.19% | 7.74% | -133.70× | Reported |
| 2022-07-03 | $1.44B | $4.69B | $790.00M | $-899.00M | $39.00M | 30.62% | 16.83% | -23.05× | Reported |
| 2022-04-03 | $1.31B | $4.66B | $779.00M | $-132.00M | $48.00M | 28.16% | 16.73% | -2.75× | Reported |
| 2022-01-02 | $1.19B | $4.53B | $754.00M | $-123.00M | $61.00M | 26.18% | 16.66% | -2.02× | Reported |
| 2021-10-03 | $1.03B | $4.28B | $734.00M | $-31.00M | $64.00M | 24.16% | 17.15% | -0.48× | Reported |
| 2021-07-04 | $769.00M | $3.97B | $286.00M | $676.00M | $61.00M | 19.39% | 7.21% | 11.08× | Reported |
| 2021-04-04 | $723.00M | $3.47B | $222.00M | $584.00M | $57.00M | 20.82% | 6.39% | 10.25× | Reported |
| 2021-01-03 | $682.00M | $3.24B | $194.00M | $580.00M | $49.00M | 21.06% | 5.99% | 11.84× | Reported |
| 2020-09-27 | $644.00M | $3.24B | $165.00M | $715.00M | $44.00M | 19.89% | 5.10% | 16.25× | Reported |
| 2020-06-28 | $623.00M | $3.35B | $150.00M | $860.00M | $44.00M | 18.59% | 4.48% | 19.55× | Reported |
| 2020-03-29 | $634.00M | $3.56B | $182.00M | $970.00M | $48.00M | 17.83% | 5.12% | 20.21× | Reported |
| 2019-12-29 | $647.00M | $3.54B | $194.00M | $985.00M | $52.00M | 18.26% | 5.48% | 18.94× | Reported |
| 2019-09-29 | $662.00M | $3.46B | $192.00M | $914.00M | $61.00M | 19.14% | 5.55% | 14.98× | Reported |
| 2019-06-30 | $670.00M | $3.40B | $194.00M | $848.00M | $65.00M | 19.68% | 5.70% | 13.05× | Reported |
| 2019-03-31 | $655.00M | $3.40B | $196.00M | $869.00M | $61.00M | 19.28% | 5.77% | 14.25× | Reported |
| 2018-12-30 | $623.00M | $3.33B | $193.00M | $883.00M | $57.00M | 18.69% | 5.79% | 15.49× | Reported |
| 2018-09-30 | $584.00M | (m) | $187.00M | $916.00M | $48.00M | (m) | (m) | 19.08× | Reported |
| 2018-07-01 | $559.00M | $3.10B | $173.00M | $856.00M | $43.00M | 18.01% | 5.58% | 19.91× | Reported |
| 2018-04-01 | $538.00M | $2.94B | $162.00M | $772.00M | $40.00M | 18.32% | 5.52% | 19.30× | Reported |
| 2017-12-31 | $546.00M | $2.75B | $164.00M | $606.00M | $37.00M | 19.84% | 5.96% | 16.38× | Reported |
| 2017-10-01 | $539.41M | $2.59B | $150.06M | $519.03M | $34.18M | 20.79% | 5.78% | 15.18× | Reported |
| 2017-07-02 | $530.41M | $2.49B | $151.06M | $499.03M | $33.18M | 21.32% | 6.07% | 15.04× | Reported |
| 2017-04-02 | $525.41M | $2.42B | $144.06M | $518.03M | $33.18M | 21.67% | 5.94% | 15.61× | Reported |
| 2017-01-01 | $504.42M | $2.40B | $129.06M | $587.03M | $33.18M | 21.03% | 5.38% | 17.69× | Reported |
| 2016-10-02 | $488.85M | $2.37B | $137.33M | $588.02M | $31.81M | 20.62% | 5.79% | 18.48× | Reported |
| 2016-07-03 | $462.16M | $2.31B | $134.98M | $568.10M | $36.42M | 19.97% | 5.83% | 15.60× | Reported |
| 2016-04-03 | $433.75M | $2.25B | $135.97M | $558.16M | $39.48M | 19.25% | 6.04% | 14.14× | Reported |
| 2016-01-03 | $401.53M | $2.22B | $132.59M | $612.84M | $42.12M | 18.09% | 5.97% | 14.55× | Reported |
| 2015-09-27 | $430.13M | $2.14B | $135.57M | $671.72M | $46.27M | 20.09% | 6.33% | 14.52× | Reported |
| 2015-06-28 | $415.98M | $2.07B | $148.01M | $650.43M | $44.43M | 20.09% | 7.15% | 14.64× | Reported |
| 2015-03-29 | $402.79M | $1.98B | $151.04M | $598.74M | $43.15M | 20.35% | 7.63% | 13.88× | Reported |
| 2014-12-28 | $388.06M | $1.86B | $152.55M | $514.71M | $41.73M | 20.85% | 8.20% | 12.33× | Reported |
| 2014-09-28 | $321.84M | $1.74B | $143.84M | $385.61M | $40.60M | 18.54% | 8.28% | 9.50× | Reported |
| 2014-06-29 | $307.71M | $1.61B | $126.58M | $311.58M | $39.56M | 19.08% | 7.85% | 7.88× | Reported |
| 2014-03-30 | $292.33M | $1.51B | $115.03M | $271.35M | $39.69M | 19.35% | 7.61% | 6.84× | Reported |
| 2013-12-29 | $276.74M | $1.42B | $105.83M | $134.11M | $39.69M | 19.47% | 7.45% | 3.38× | Reported |
| 2013-09-29 | $256.92M | $1.34B | $100.26M | $119.67M | $39.33M | 19.13% | 7.46% | 3.04× | Reported |
| 2013-06-30 | $240.02M | $1.27B | $95.92M | $123.02M | $38.86M | 18.87% | 7.54% | 3.17× | Reported |
| 2013-03-31 | $243.64M | $1.21B | $95.51M | $105.99M | $38.32M | 20.19% | 7.92% | 2.77× | Reported |
| 2012-12-30 | $231.03M | $1.15B | $94.32M | $200.75M | $37.78M | 20.12% | 8.21% | 5.31× | Reported |
| 2012-09-30 | $219.63M | $1.09B | $91.96M | $168.71M | $37.38M | 20.16% | 8.44% | 4.51× | Reported |
| 2012-07-01 | $215.97M | $1.04B | $93.46M | $156.66M | $36.69M | 20.79% | 9.00% | 4.27× | Reported |
| 2012-04-01 | $195.55M | $1.05B | $93.08M | $179.69M | $36.60M | 18.70% | 8.90% | 4.91× | Reported |
| 2012-01-01 | $196.91M | $1.06B | $92.09M | $199.46M | $34.79M | 18.66% | 8.72% | 5.73× | Reported |
| 2011-10-02 | $197.20M | $1.07B | $90.12M | $240.83M | $31.92M | 18.49% | 8.45% | 7.54× | Reported |
| 2011-07-03 | $191.60M | $1.07B | $83.51M | $261.40M | $29.32M | 17.93% | 7.81% | 8.92× | Reported |
| 2011-04-03 | $184.47M | $993.13M | $76.69M | $242.82M | $26.03M | 18.57% | 7.72% | 9.33× | Reported |
| 2011-01-02 | $177.95M | $902.74M | $71.64M | $211.65M | $24.60M | 19.71% | 7.94% | 8.60× | Reported |
| 2010-10-03 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-07-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-04-04 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-01-03 | $140.62M | $666.32M | $60.81M | $125.60M | $23.72M | 21.10% | 9.13% | 5.30× | Reported |
| 2009-09-27 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-28 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-28 | $99.96M | $573.23M | $47.69M | $80.46M | $22.21M | 17.44% | 8.32% | 3.62× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| WATERS CORP /DE/ (WAT) | United States | $42.297B | 224.28 |
| AGILENT TECHNOLOGIES, INC. (A) | United States | $48.720B | 27.14 |
| METTLER TOLEDO INTERNATIONAL INC/ (MTD) | $30.436B | 30.62 | |
| REVVITY, INC. (RVTY) | United States | $16.814B | 53.44 |
| Avantor, Inc. (AVTR) | United States | $10.501B | -9.72 |
| BRUKER CORP (BRKR) | United States | $9.706B | -128.75 |
| Alamar Biosciences, Inc. (ALMR) | United States | $2.300B | |
| Cytek Biosciences, Inc. (CTKB) | United States | $0.744B | -7.15 |
| PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) | United States | $0.491B | -3.95 |
| 908 Devices Inc. (MASS) | United States | $0.476B | -9.53 |